Citations

Clear

3042 citation(s) found for "Kumar, S".

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
Makwana, Bhargav , Patel, Manav, Panchal, Krisha , Shah, Jui , Kumar, Ashish , Patel, Tirth, Kosiborod, Mikhail, Ramsey, Kathryn Moynihan , Nohria, Anju, Butler, Javed , Ganatra, Sarju , Ramsey, David J. , Dani, Sourbha S. , Khadke, Sumanth , Kosiborod, Mikhail , Fonarow, Gregg C. , Nohria, Anju

Mayo Clinic

JAMA Network Open | August 11, 2025 | Volume: 8 | Issue: 8 | Pages: e2526321

10.1001/jamanetworkopen.2025.26321 | PMID 40788647 Get It

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with increased risk of diabetic retinopathy (DR) and nonarteritic anterior ischemic optic neuropathy (NAION). The risk of sight-threatening complications associated with GLP-1 RAs is underexamined. Objective To investigate whether the use of GLP-1 RAs in patients with T2D is associated with the development of DR, NAION, or DR complications. Design, Setting, and Participants This retrospective cohort study of adults (aged ≥18 years) with T2D and a recent hemoglobin A 1c level of 6.5% or higher was conducted between January 1, 2015, and September 30, 2022, using the TriNetX database. The cohort was divided into 2 groups, adjusted for baseline characteristics through propensity score matching (PSM), based on whether the individuals received prescriptions for a GLP-1 RA. The statistical analysis was conducted on October 10, 2024. Exposures At least 2 prescriptions of a GLP-1 RA given 6 months apart. Main Outcomes and Measures Cox proportional hazard regression models were used to evaluate the primary outcome: association between GLP-1 RAs and the risk of incident DR, NAION, or sight-threatening complications over a 2-year follow-up period. Results After PSM, 185 066 individuals (mean [SD] age, 59.0 [12.5] years; 93 389 females [50.5%]) were prescribed GLP-1 receptor agonists. Use of GLP-1 RAs was associated with an increased incidence of DR (hazard ratio [HR], 1.07; 95% CI, 1.03-1.11), while no statistically significant difference was observed in the risk of NAION (HR, 1.26; 95% CI, 0.94-1.70). In a subgroup analysis of 32 695 patients with preexisting DR, GLP-1 RAs were not associated with progression to proliferative DR (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) but were associated with a lower occurrence of vitreous hemorrhages (HR, 0.74; 95% CI, 0.68-0.80), neovascular glaucoma (HR, 0.78; 95% CI, 0.68-0.88), or blindness (HR, 0.77; 95% CI, 0.73-0.82). Conclusions and Relevance In this cohort study of individuals with T2D, GLP-1 RA use was associated with a modestly increased risk of incident DR; however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.
Saddle Nose in Granulomatosis With Polyangiitis (GPA) vs. Non‐GPA Patients With Septal Perforations
Kumar, Nitish , Gomes, Pedro Lança , Jett, Savannah D., Bansberg, Stephen F. , Marino, Michael J. , Lal, Devyani , Miglani, Amar , Jett, Savannah, Kumar, Nitish , Lal, Devyani

Mayo Clinic

Laryngoscope Investigative Otolaryngology | August 11, 2025 | Volume: 10 | Issue: 4 | Pages: No page available

10.1002/lio2.70217 | PMID 40792077 Get It

ABSTRACTObjectivesSaddle nose deformity (SND) can be associated with nasal septal perforation (NSP). Both SND and NSP are observed in granulomatosis with polyangiitis (GPA) patients. This study aimed to compare the prevalence and severity of SND in GPA vs. non‐GPA patients with NSP.MethodologyNSP patients who visited tertiary rhinology or facial plastic surgery clinics from January 2010 through December 2023 were grouped into GPA and non‐GPA cohorts. The area of NSP, SND incidence, and SND severity (Daniel and Brenner's classification) were compared between the cohorts.ResultsOf 168 patients identified with NSP, 18 had GPA and 150 had non‐GPA diagnoses. Twelve GPA patients and 10 non‐GPA patients had SND. The odds ratio for SND association in GPA patients with NSP vs. non‐GPA patients was 31.3 (95% CI: 9.5–102.9), and 19.4 (95% CI: 4.3–87.7) after controlling for the NSP area. GPA patients with SND had a larger NSP area (median 670 mm2, IQR: 315.5–1061.3) compared to non‐GPA patients with SND (175.3 mm2, 113.1–204.1; p < 0.001). The severity of SND was similar between GPA and the non‐GPA group (p = 0.09). The area of NSP did not predict the severity of SND (p = 0.17).ConclusionGPA diagnosis was associated with larger NSPs and a higher risk of SND compared to non‐GPA etiologies; however, the severity of saddling did not differ between GPA and non‐GPA etiologies. GPA is an independent risk factor associated with SND irrespective of the size of septal perforation. The NSP area did not predict the severity of SND.Level of Evidence: 4.
Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling
Sloan, Anthony , Bukenya, George, Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair, Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Lohoff, Falk W. , Goodman, Wendy A., Miller, Tyler E., O’Connor, Christine M. , Lathia, Justin D. , Sloan, Anthony R , Luo, Jingqin , Rubin, Joshua B , Stavrou, Evi X , O'Connor, Christine M , Cameron, Scott J , Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair , Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Stavrou, Evi X. , Goodman, Wendy A., Miller, Tyler E., Nieman, Marvin T. , Sangwan, Naseer , Chan, Timothy An-thy , Khorana, Alok A. , Dhawan, Andrew , Cameron, Scott J.

Mayo Clinic

No container title available | August 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.06.668464 | PMID 41959130 Get It

Abstract Sex differences in cancer outcome, including that of glioblastoma (GBM), are shaped by biological, hormonal, and immunological factors and impact disease progression, treatment responses, survival, and tumor microenvironment (TME) interactions. Platelets regulate the immune responses and tumor progression in many cancers, but it is not clear how they contribute to these sex-based differences by affecting the dynamics of the TME. Here, we show that GBM patients exhibit heightened platelet reactivity driven by PAR4 signaling. In murine GBM models, both pharmacological inhibition of PAR4 using BMS986120 and genetic deletion of PAR4 significantly prolong survival in females but not males. This survival advantage is estrogen dependent: it is preserved in chromosomal male-hormonal female mice within the four-core genotype model and is rescued in ovariectomized mice treated with estrogen. The survival benefit is TME specific and is mediated by platelet-driven enhancement of CD8⁺ T cell infiltration into the tumor. Inhibition of platelet PAR4 signaling increases calcium signaling through an estrogen-dependent interaction between PAR4 and estrogen receptor β (ERβ)—a receptor interaction not previously described. PAR4-activated platelets within the TME suppress CD8⁺ T cell function, and depletion of CD8⁺ T cells abolishes both the tumor-induced platelet reactivity and the survival benefit conferred by PAR4 inhibition. These findings establish platelet-mediated PAR4 signaling as a critical driver of tumor progression and identify sex-specific immune responses as key to therapeutic efficacy.
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, Aryan , Raju, Arvind Kumar Venkataramana , Gajjar, Amar , Menon, Mythili, Shah, Syed Asfand Yar , Weinberg, Andrew M., Raju, Arvind Kumar , Gajjar, Amani, Dani, Sourbha S.

Mayo Clinic

Biomedicines | August 7, 2025 | Volume: 13 | Issue: 8 | Pages: 1924

10.3390/biomedicines13081924 | PMID 40868177 Get It

Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. These conditions altogether accelerate adverse outcomes when they coexist. Recent evidence has shown that the function of glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) alleviate stress on multiple organs. SGLT2i has been demonstrated to benefit heart failure, hemodynamic regulation, and renal protection while GLP-1RA on the other hand has been shown to demonstrate a strong impact on glycemic management, weight loss, and atherosclerotic cardiovascular disease. This review will aim to understand and evaluate the mechanistic rationalization, clinical evidence, and the potential therapeutic treatment of SGLT2 inhibitors and GLP-1 receptor agonists to treat individuals who have CKM syndrome. This analysis also assesses whether combination therapy can be a synergistic approach that may benefit patients but is still underutilized because of the lack of clear guidelines, the associated costs, and disparities in accessibility. Therefore, in this review, we will be discussing the combination therapy’s additive and synergistic effects, current recommendations and clinical evidence, and mechanistic insights of these GLT2 inhibitors and GLP-1 receptor agonists in CKM syndrome patients. Overall, early and combination usage of GLP-1RA and SGLT2i may be essential to demonstrating a significant shift in modern cardiometabolic therapy toward patient-centered care.
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (&lt;3 vs 3-6 vs &gt;6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
Comparative Outcomes of Intra-Aortic Balloon Pump Versus Percutaneous Left Ventricular Assist Device in High-Risk Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Sivasubramanian, Dhiran , Senthilkumar, Virushnee, Palanisamy, Nithish Nanda, Bilgaiyan, Rashi, Aravind, Smrti , Kumar, Sri Drishaal, Balasubramanian, Aishwarya , Sanil, Sathwik , Balasubramanian, Karthick, Kamaladasan, Dharssini, Pilathodan, Hashwin, Shankar, Kiruba, Nanda Palanisamy, Nithish , Kumar, Sri Drishaal, Balasubramanian, Aishwarya

Mayo Clinic

Journal of Clinical Medicine | August 5, 2025 | Volume: 14 | Issue: 15 | Pages: 5430

10.3390/jcm14155430 | PMID 40807051 Get It

Background/Objectives: High-risk percutaneous coronary interventions (HR-PCIs) often require mechanical circulatory support (MCS) to maintain hemodynamic stability. Intra-aortic balloon pump (IABP) and percutaneous left ventricular assist device (PLVAD) are two commonly used MCS devices that differ in their mechanisms. We aimed to evaluate and compare the clinical outcomes associated with IABP and PLVAD use in HR-PCIs without cardiogenic shock. Methods: We conducted a search of PubMed, Scopus, Cochrane, Mendeley, Web of Science, and Embase to identify relevant randomized controlled trials and cohort studies, and we included 13 studies for the systematic review and meta-analysis. The primary goal was to define the difference in early mortality (in-hospital and 30-day mortality), major bleeding, and major adverse cardiovascular event (MACE) components (cardiogenic shock, acute kidney injury (AKI), and stroke/TIA) in IABP and PLVAD. We used a random-effects model with the Mantel–Haenszel statistical method to estimate odds ratios (ORs) and 95% confidence intervals. Results: Among 1 trial and 12 cohort studies (35,554 patients; 30,351 IABP and 5203 PLVAD), HR-PCI with IABP was associated with a higher risk of early mortality (OR = 1.53, 95% CI [1.21, 1.94]) and cardiogenic shock (OR = 2.56, 95% CI [1.98, 3.33]) when compared to PLVAD. No significant differences were found in the rates of arrhythmia, major bleeding, AKI, stroke/TIA, or hospital length of stay. Conclusions: In high-risk PCIs, PLVAD use is associated with lower early mortality and cardiogenic shock risk compared to IABP, with no significant differences in other major outcomes.
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Dhakal, Binod , Akhtar, Othman Salim , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed, Martinez, Mariola Alejandra Vazquez, Wagner, Charlotte B , Davis, James A. , Afrough, Aimaz , Bhutani, Manisha , Freeman, Ciara L. , Mikkilineni, Lekha , Raza, Shahzad , Anderson, Larry D. , Kapoor, Prashant , Hosoya, Hitomi , Gaballa, Mahmoud , Midha, Shonali , Alsina, Melissa , Sborov, Douglas W. , Patel, Krina K. , Lin, Yi , Ferreri, Christopher J. , Kumar, Anupama, Cowan, Andrew J., Sidana, Surbhi , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed , Vazquez-Martinez, Mariola A , Wagner, Charlotte , Davis, James A , Castaneda Puglianini, Omar , Dima, Danai , Bhutani, Manisha , Parrondo, Ricardo D , Freeman, Ciara L , Anderson, Larry D , Hosoya, Hitomi , Chhabra, Saurabh , Grajales-Cruz, Ariel F , Sborov, Douglas W , Patel, Krina , Hansen, Doris K , Costa, Luciano J , Merz, Maximilian , Sidana, Surbhi , Raza, Shahzad , Dhakal, Binod , Fandrei, David , Pan, Darren , Richard, Shambavi , Rees, Matthew J. , Costello, Patrick , Vazquez‐Martinez, Mariola , Pasvolsky, Oren , Puglianini, Omar Castañeda , Reshef, Ran , Dima, Danai , Nadeem, Omar , Chhabra, Saurabh , Grajales‐Cruz, Ariel , Gagelmann, Nico , Hansen, Doris K. , Costa, Luciano J. , Merz, Maximilian

Mayo Clinic

Blood | August 1, 2025 | Volume: 146 | Issue: 17 | Pages: 2063-2072

10.1182/blood.2025029773 | PMID 40749169 Get It

Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein–coupled receptor, family C, group 5, member D (GPRC5D)–targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
Penetrating Bladder Trauma Leading to a Rectovesical Fistula: A Rare Complication of Bicycle Handlebar Injury in a Paediatric Patient
Kavirayani, Vaishnavi , Pai, Nitin G , Kumar, Vijay , Thotan, Sundeep Payyanur

Mayo Clinic

Journal of Indian Association of Pediatric Surgeons | July 30, 2025 | Volume: 30 | Issue: 6 | Pages: 794-796

10.4103/jiaps.jiaps_99_25 | PMID 41293506 Get It

A BSTRACT An adolescent boy presented with a history of penetrating trauma from a bicycle handlebar injury to the left lower abdomen. A computed tomography (CT) scan and a diagnostic laparoscopy showed extraperitoneal bladder rupture, which was repaired. In the postoperative period, a micturating cystourethrogram revealed a rectovesical fistula (RVF), which was managed conservatively with a Foley catheter. This case depicts a rare complication of RVF in a case of penetrating trauma abdomen managed conservatively with a unique mechanism of injury.
A Cure, a Cure, My Kingdom for a Cure…
Kumar, Shaji , Kumar, Shaji K , Lonial, Sagar

Mayo Clinic

Journal of Clinical Oncology | July 29, 2025 | Volume: 43 | Issue: 25 | Pages: 2763-2765

10.1200/jco-25-01258 | PMID 40729626 Get It

Same-Day Hospital Discharge Is Feasible for a Variety of Urologic Surgeries When Using a Virtual Hybrid Care Hotel
Hampton, Sarah, Perry, Alan G., Kumar, Neal, Hochwald, Alex, Ma, R. , Pak, Raymond W., Petrou, Steven P. , Thiel, David D. , Nazario, Maura, Pathak, Ram A. , Hochwald, Alex P, Ma, Renny, Dora, Chandler , Ma, Renny, Broderick, Gregory A. , Lyon, Timothy D. , Chadha, Ryan

Mayo Clinic

Urology Practice | July 25, 2025 | Volume: 12 | Issue: 6 | Pages: 683-690

10.1097/upj.0000000000000879 | PMID 40709932 Get It